Jupiter, Florida — November 5, 2025 — Leads & Copy — Jupiter Neurosciences, Inc. (NASDAQ:JUNS) announced that the FDA has cleared its IND application to begin a Phase 2a clinical trial of JOTROL™ for Parkinson’s disease.
The FDA’s clearance marks a regulatory milestone, enabling the company to begin enrollment in its Phase 2a trial to evaluate the safety and tolerability of JOTROL™ in Parkinson’s patients.
CEO Christer Rosén said the FDA clearance is an important step forward for Jupiter and the Parkinson’s community, as preclinical evidence suggests JOTROL™ has neuroprotective benefits.
Jupiter will continue its collaboration with Zina Biopharmaceuticals, LLC, and expects to begin trial enrollment in early 2026.
Contact:
IR@jupiterneurosciences.com
JUNS@redchip.com
Source: Jupiter Neurosciences, Inc.
